The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals (ANIP) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANI Pharmaceuticals is one of 956 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 14.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ANIP has moved about 64.2% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 1.6% on average. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Celldex Therapeutics (CLDX). The stock has returned 9% year-to-date.
In Celldex Therapeutics' case, the consensus EPS estimate for the current year increased 1.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 470 individual companies and currently sits at #90 in the Zacks Industry Rank. This group has gained an average of 8.8% so far this year, so ANIP is performing better in this area. Celldex Therapeutics is also part of the same industry.
Investors with an interest in Medical stocks should continue to track ANI Pharmaceuticals and Celldex Therapeutics. These stocks will be looking to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
